Tranzyme

Pharma

GI treatments firm Tranzyme secures $9.3M in debt financing

Gastrointestinal treatments company Tranzyme Pharma (NASDAQ:TZYM) has secured $9.3 million in financing — enough to carry the company through the third quarter. Durham, North Carolina-based Tranzyme said that the loan came from an amendment and restatement of its existing debt financing facility with Oxford Finance and Horizon Technology Finance Corporation (NASDAQ:HRZN). Tranzyme will use a […]

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.